136 related articles for article (PubMed ID: 35084368)
1. The significance of CUX1 and chromosome 7 in myeloid malignancies.
Jotte MRM; McNerney ME
Curr Opin Hematol; 2022 Mar; 29(2):92-102. PubMed ID: 35084368
[TBL] [Abstract][Full Text] [Related]
2. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.
McNerney ME; Brown CD; Wang X; Bartom ET; Karmakar S; Bandlamudi C; Yu S; Ko J; Sandall BP; Stricker T; Anastasi J; Grossman RL; Cunningham JM; Le Beau MM; White KP
Blood; 2013 Feb; 121(6):975-83. PubMed ID: 23212519
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical and biological implications of
Aly M; Ramdzan ZM; Nagata Y; Balasubramanian SK; Hosono N; Makishima H; Visconte V; Kuzmanovic T; Adema V; Nazha A; Przychodzen BP; Kerr CM; Sekeres MA; Abazeed ME; Nepveu A; Maciejewski JP
Blood Adv; 2019 Jul; 3(14):2164-2178. PubMed ID: 31320321
[TBL] [Abstract][Full Text] [Related]
4. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
An N; Khan S; Imgruet MK; Gurbuxani SK; Konecki SN; Burgess MR; McNerney ME
Blood; 2018 Jun; 131(24):2682-2697. PubMed ID: 29592892
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).
McNerney ME; Brown CD; Peterson AL; Banerjee M; Larson RA; Anastasi J; Le Beau MM; White KP
Br J Haematol; 2014 Aug; 166(4):550-6. PubMed ID: 24931631
[TBL] [Abstract][Full Text] [Related]
6. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN.
Thoennissen NH; Lasho T; Thoennissen GB; Ogawa S; Tefferi A; Koeffler HP
Am J Hematol; 2011 Aug; 86(8):703-5. PubMed ID: 21674579
[No Abstract] [Full Text] [Related]
7. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
Imgruet MK; Lutze J; An N; Hu B; Khan S; Kurkewich J; Martinez TC; Wolfgeher D; Gurbuxani SK; Kron SJ; McNerney ME
Blood; 2021 Sep; 138(9):790-805. PubMed ID: 34473231
[TBL] [Abstract][Full Text] [Related]
8. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
Hosono N
Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
[TBL] [Abstract][Full Text] [Related]
9. [Monosomy 7: recent progress].
Inaba T; Nagamachi A
Rinsho Ketsueki; 2019; 60(9):1020-1026. PubMed ID: 31597823
[TBL] [Abstract][Full Text] [Related]
10. Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features.
Dermawan JK; Wensel C; Visconte V; Maciejewski JP; Cook JR; Bosler DS
Am J Clin Pathol; 2022 Apr; 157(4):586-594. PubMed ID: 34661647
[TBL] [Abstract][Full Text] [Related]
11. Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.
Wong JC; Zhang Y; Lieuw KH; Tran MT; Forgo E; Weinfurtner K; Alzamora P; Kogan SC; Akagi K; Wolff L; Le Beau MM; Killeen N; Shannon K
Blood; 2010 Jun; 115(22):4524-32. PubMed ID: 20233966
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathogenesis of MDS.
Look AT
Hematology Am Soc Hematol Educ Program; 2005; ():156-60. PubMed ID: 16304374
[TBL] [Abstract][Full Text] [Related]
13. Recurrent genetic defects on chromosome 7q in myeloid neoplasms.
Hosono N; Makishima H; Jerez A; Yoshida K; Przychodzen B; McMahon S; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Gómez-Seguí I; Verma AK; McDevitt MA; Sekeres MA; Ogawa S; Maciejewski JP
Leukemia; 2014 Jun; 28(6):1348-51. PubMed ID: 24429498
[No Abstract] [Full Text] [Related]
14. The enigma of monosomy 7.
Inaba T; Honda H; Matsui H
Blood; 2018 Jun; 131(26):2891-2898. PubMed ID: 29615405
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.
An N; Khan S; Imgruet MK; Jueng L; Gurbuxani S; McNerney ME
Oncogene; 2023 Mar; 42(12):881-893. PubMed ID: 36725889
[TBL] [Abstract][Full Text] [Related]
16. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A
Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218
[TBL] [Abstract][Full Text] [Related]
17. CUX1 in leukemia: dosage matters.
Boultwood J
Blood; 2013 Feb; 121(6):869-71. PubMed ID: 23393017
[No Abstract] [Full Text] [Related]
18. [Significance of chromosome 7 abnormalities in myeloid malignancies].
Shi WH; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1739-43. PubMed ID: 25543507
[TBL] [Abstract][Full Text] [Related]
19. Inactivating CUX1 mutations promote tumorigenesis.
Wong CC; Martincorena I; Rust AG; Rashid M; Alifrangis C; Alexandrov LB; Tiffen JC; Kober C; ; Green AR; Massie CE; Nangalia J; Lempidaki S; Döhner H; Döhner K; Bray SJ; McDermott U; Papaemmanuil E; Campbell PJ; Adams DJ
Nat Genet; 2014 Jan; 46(1):33-8. PubMed ID: 24316979
[TBL] [Abstract][Full Text] [Related]
20. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
Chen C; Liu Y; Rappaport AR; Kitzing T; Schultz N; Zhao Z; Shroff AS; Dickins RA; Vakoc CR; Bradner JE; Stock W; LeBeau MM; Shannon KM; Kogan S; Zuber J; Lowe SW
Cancer Cell; 2014 May; 25(5):652-65. PubMed ID: 24794707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
